Comparative study of triple intravenous chemotherapy versus dual chemotherapy combined with hepatic arterial infusion in patients with liver metastases from colorectal cancer - Scorecard - MDSpire
Advertisement
Comparative study of triple intravenous chemotherapy versus dual chemotherapy combined with hepatic arterial infusion in patients with liver metastases from colorectal cancer
Clinical Scorecard: Evaluation of Triplet Intravenous Chemotherapy Versus Dual Chemotherapy with Hepatic Arterial Infusion in Colorectal Cancer Patients with Liver Metastases
At a Glance
Category
Detail
Condition
Key Mechanisms
Comparison of FOLFOXIRI triplet chemotherapy versus FOLFIRI combined with hepatic arterial infusion chemotherapy (HAIC) based on study findings.
Target Population
Care Setting
Key Highlights
FOLFIRI plus HAIC group showed higher objective response rate (ORR) and disease control rate (DCR) compared to FOLFOXIRI group based on study results.
Progression-free survival (PFS) was longer in FOLFIRI plus HAIC group (10.3 months) versus FOLFOXIRI group (8.2 months) according to study data.
R0 resection rate was higher in FOLFIRI plus HAIC group (21.5%) compared to FOLFOXIRI group (9.0%) as per study findings.
Grade 3/4 adverse events were comparable between groups, with a lower incidence of neutropenia in FOLFIRI plus HAIC group based on study results.
HAIC-related complications were infrequent and manageable according to study observations.
Guideline-Based Recommendations
Diagnosis
Management
Consider FOLFIRI plus HAIC for patients with unresectable liver metastases based on study findings.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
FOLFIRI plus HAIC may provide improved disease control and PFS compared to FOLFOXIRI based on study results.
